Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $312,250.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin McCulloch sold 25,000 shares of the company’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $12.49, for a total transaction of $312,250.00. Following the transaction, the insider owned 1,559,208 shares of the company’s stock, valued at approximately $19,474,507.92. The trade was a 1.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Mcculloch also recently made the following trade(s):

• On Monday, November 2nd, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $10.23, for a total transaction of $153,450.00.
• On Thursday, October 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $9.41, for a total transaction of $141,150.00.
• On Monday, September 28th, Kevin McCulloch sold 25,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00.
• On Tuesday, September 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.49, for a total transaction of $127,350.00.

Xeris Biopharma Stock Performance

Shares of Xeris Biopharma stock opened at $15.20 on Monday. The firm has a market cap of $2.78 billion, a price-to-earnings ratio of -303.94 and a beta of 0.61. Xeris Biopharma Holdings, Inc. has a 52-week low of $5.25 and a 52-week high of $15.21. The company’s 50-day simple moving average is $9.62 and its 200-day simple moving average is $7.62. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. Xeris Biopharma had a negative net margin of 1.76% and a positive return on equity of 429.43%. The firm had revenue of $107.23 million during the quarter, compared to the consensus estimate of $101.68 million. As a group, equities research analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current year.

Institutional Investors Weigh In On Xeris Biopharma

Several institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Xeris Biopharma in the second quarter valued at approximately $115,042,000. Legal & General Group Plc acquired a new position in shares of Xeris Biopharma during the 2nd quarter worth approximately $15,941,000. Parkman Healthcare Partners LLC acquired a new position in shares of Xeris Biopharma during the 2nd quarter worth approximately $14,316,000. Bank of America Corp DE acquired a new position in shares of Xeris Biopharma during the 2nd quarter worth approximately $11,065,000. Finally, Vilga Financial Planning LLC purchased a new stake in Xeris Biopharma in the 3rd quarter valued at approximately $10,134,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma News Roundup

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q3 results beat expectations: Xeris reported earnings of $0.06 per share versus a $0.03 consensus estimate, while revenue of $107.23 million exceeded forecasts of $101.68 million. The results provide evidence of stronger-than-expected performance. Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
• Positive Sentiment: Analysts raised targets: Oppenheimer reaffirmed its “outperform” rating and lifted its target to $21 from $18. HC Wainwright kept a “buy” rating and raised its target to $18 from $10. These revisions suggest greater optimism about Xeris’s prospects. Oppenheimer ratings HC Wainwright ratings
• Positive Sentiment: Recorlev sales outlook: CEO John Shannon reportedly sees the drug approaching $1 billion in annual sales three to four years earlier than previously expected, a potentially meaningful growth driver. CEO comments on Recorlev sales outlook
• Neutral Sentiment: Insider Kevin McCulloch sold 25,000 shares under a pre-arranged Rule 10b5-1 plan, a modest reduction; he retained more than 1.55 million shares. SEC Form 4 filing
• Negative Sentiment: Cautious analyst view: Piper Sandler reaffirmed “neutral” despite raising its target to $12 from $8. That target remains below the share price cited in the report, signaling valuation concerns. Piper Sandler ratings

Analysts Set New Price Targets

XERS has been the topic of a number of recent analyst reports. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. HC Wainwright raised their target price on Xeris Biopharma from $10.00 to $18.00 and gave the company a “buy” rating in a report on Friday. Oppenheimer reissued an “outperform” rating and issued a $21.00 target price (up from $18.00) on shares of Xeris Biopharma in a report on Friday. Leerink Partners boosted their target price on shares of Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a research report on Thursday, September 10th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $12.00 price target (up from $8.00) on shares of Xeris Biopharma in a research note on Friday. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Xeris Biopharma currently has an average rating of “Moderate Buy” and a consensus target price of $16.20.

About Xeris Biopharma

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.